Cargando…

Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases

SIMPLE SUMMARY: HER2-equivocal cases represent around 15% of breast carcinomas, and 20–40% of them are HER2-amplified. The distinction between HER2-amplified and non-amplified cases is of great importance for patient management, and in this study, we investigated the performance of STRAT4 (a RT-qPCR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carretero-Barrio, Irene, Caniego-Casas, Tamara, Rosas, Marta, Sánchez, María Concepción, Martínez-Jáñez, Noelia, Chiva, Miguel, Sarrió, David, Moreno-Bueno, Gema, Palacios, José, Pérez-Mies, Belén
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046044/ https://www.ncbi.nlm.nih.gov/pubmed/36980575 http://dx.doi.org/10.3390/cancers15061688

Ejemplares similares

Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
por: López-García, M. Ángeles, et al.
Publicado: (2020)

Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
por: Agersborg, Sally, et al.
Publicado: (2018)

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines
por: Press, Michael F., et al.
Publicado: (2018)

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features
por: Rosa-Rosa, Juan Manuel, et al.
Publicado: (2019)

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
por: Crespo, James, et al.
Publicado: (2020)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
por: Gámez-Chiachio, Manuel, et al.
Publicado: (2022)

Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
por: Cardillo, Anthony B., et al.
Publicado: (2023)

Cytological and molecular characterization of secretory breast carcinoma
por: Carretero‐Barrio, Irene, et al.
Publicado: (2022)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables
por: A. Musa, Zaidoon, et al.
Publicado: (2017)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors
por: Pérez-Mies, Belén, et al.
Publicado: (2022)

RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies
por: Caniego-Casas, Tamara, et al.
Publicado: (2022)

Is HER2 amplification predictable by digital immunohistochemistry?
por: Micsik, Tamás, et al.
Publicado: (2013)

Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma
por: González-Martínez, Silvia, et al.
Publicado: (2021)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

Progression to lung fibrosis in severe COVID-19 patients: A morphological and transcriptomic study in postmortem samples
por: Pérez-Mies, Belén, et al.
Publicado: (2022)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis
por: González-Martínez, Silvia, et al.
Publicado: (2021)

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
por: Liu, Yuanyuan, et al.
Publicado: (2019)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia
por: Joshi, Sunil K., et al.
Publicado: (2020)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
por: Kong, Hui, et al.
Publicado: (2022)

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
por: Landgraf, Ralf
Publicado: (2007)

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases
por: Ayad, E., et al.
Publicado: (2014)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
por: Ji, Hongfei, et al.
Publicado: (2015)

Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer
por: Gupta, Swati, et al.
Publicado: (2019)

The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry‐equivocal invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2022)

Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification
por: Ercolani, Cristiana, et al.
Publicado: (2017)

Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment
por: Erber, Ramona, et al.
Publicado: (2021)

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors
por: Marotta, Michael, et al.
Publicado: (2017)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
por: Torres-Jiménez, Javier, et al.
Publicado: (2022)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ct0a0mlgdaj1v8keaf1k5kbvim